Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
⚠️ Updated analysis. The primary endpoint (PFS by BICR) was previously reported. This analysis reports updated overall survival at 28·4 months median follow-up.
🎯 Clinical Bottom Line
Trastuzumab deruxtecan is superior to trastuzumab emtansine in the second-line treatment of HER2-positive metastatic breast cancer. At this prespecified interim analysis, the overall survival benefit crossed the prespecified statistical boundary, confirming that the profound PFS advantage translates into a survival gain. T-DXd is now the preferred second-line agent, displacing T-DM1 from the position it held since EMILIA. ILD remains the key safety concern — though no fatal ILD events occurred in this trial.
Key Result: PFS by BICR — 28·8 vs 6·8 months, HR 0·33 (95% CI 0·26–0·43; nominal p<0·0001)
OS (key secondary): Not reached vs not reached — HR 0·64 (95% CI 0·47–0·87; p=0·0037) — crossed prespecified boundary of 0·013
Safety Signal: Adjudicated ILD/pneumonitis in 15% with T-DXd vs 3% with T-DM1; no grade 4 or 5 ILD events in either arm
✅ Patient Eligibility
Must Have:
- HER2-positive (centrally confirmed)
- Unresectable or metastatic breast cancer
- Prior trastuzumab and taxane (in advanced/metastatic setting, or recurrence within 6 months of neoadjuvant/adjuvant)
- ECOG PS 0–1
- ≥1 measurable lesion per RECIST 1.1
Cannot Have:
- Active or symptomatic brain metastases (previously treated/inactive permitted)
💊 Dosing Quick Guide
Experimental Regimen
Trastuzumab deruxtecan: 5·4 mg/kg IV every 3 weeks Cycle: 21 days Duration: Until progression or unacceptable toxicity Median treatment duration: 18·2 months (IQR 9·0–29·4)
Control Regimen
Trastuzumab emtansine: 3·6 mg/kg IV every 3 weeks Median treatment duration: 6·9 months (IQR 2·8–12·3)
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - Dose reduction levels: 5·4 → 4·4 → 3·2 mg/kg; discontinue if further reduction needed - ILD: Permanently discontinue for grade ≥2 ILD - Monitoring: CBC prior to each dose; pulmonary imaging at baseline and as clinically indicated
Mechanism: Trastuzumab deruxtecan is an antibody-drug conjugate comprising an anti-HER2 antibody linked to a topoisomerase I inhibitor payload (DXd) via a cleavable linker, enabling targeted intracellular drug delivery with a bystander killing effect [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | T-DXd (n=257) | T-DM1 (n=261) |
|---|---|---|
| Neutrophil count decreased | 41 (16%) | 8 (3%) |
| Anaemia | 24 (9%) | 17 (7%) |
| Platelet count decreased | 20 (8%) | 52 (20%) |
| Nausea | 18 (7%) | 1 (<1%) |
| WBC count decreased | 16 (6%) | 2 (<1%) |
| Fatigue | 15 (6%) | 2 (<1%) |
| AST increased | 2 (<1%) | 14 (5%) |
⚠️ Interstitial Lung Disease/Pneumonitis (adjudicated):
- T-DXd: Any grade 39 (15%), Grade 1: 11 (4%), Grade 2: 26 (10%), Grade 3: 2 (<1%), Grade 4/5: 0
- T-DM1: Any grade 8 (3%), Grade 1: 4 (2%), Grade 2: 3 (1%), Grade 3: 1 (<1%), Grade 4/5: 0
Key safety metrics:
- Discontinuations due to AE (drug-related): 51 (20%) vs 17 (7%)
- Dose reductions (drug-related): 65 (25%) vs 38 (15%)
- Dose interruptions (drug-related): 108 (42%) vs 45 (17%)
- Serious AEs: 65 (25%) vs 58 (22%)
📊 Key Numbers
Median follow-up: 28·4 months (IQR 22·1–32·9) T-DXd; 26·5 months (IQR 14·5–31·3) T-DM1
| Outcome | T-DXd (n=261) | T-DM1 (n=263) | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS by BICR (primary) | 28·8 mo | 6·8 mo | 0·33 (0·26–0·43) | nominal p<0·0001 |
| OS (key secondary) | NR | NR | 0·64 (0·47–0·87) | 0·0037 |
| ORR by BICR | 79% | 35% | — | — |
| DOR by BICR | 36·6 mo | 23·8 mo | — | — |
| PFS by investigator | 29·1 mo | 7·2 mo | 0·30 (0·24–0·38) | nominal p<0·0001 |
| PFS2 (exploratory) | 40·5 mo | 25·7 mo | 0·47 (0·35–0·62) | — |
OS rates: 12-month: 94·1% vs 86·0% | 24-month: 77·4% vs 69·9%
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| DESTINY-Breast03 | T-DXd vs T-DM1 | HER2+ mBC, prior trastuzumab + taxane, 2L+ | PFS by BICR | HR 0·33 (0·26–0·43) | [1] |
| EMILIA | T-DM1 vs lapatinib + capecitabine | HER2+ mBC, prior trastuzumab + taxane | PFS by IRF | see [4] | [4] |
| HER2CLIMB | Tucatinib + trastuzumab + capecitabine vs control | HER2+ mBC, post trastuzumab/pertuzumab/T-DM1 | PFS | see [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
HR positive: OS HR 0·76 (95% CI 0·50–1·14) vs HR negative: 0·55 (0·35–0·87) — benefit directionally consistent, CI crosses 1·0 in HR+
Brain metastases (Yes): OS HR 0·54 (95% CI 0·29–1·03) vs No: 0·66 (0·47–0·94) — trending benefit in brain mets subgroup
Prior lines ≥3: OS HR 0·55 (95% CI 0·34–0·89) vs <3: 0·70 (0·47–1·04) — benefit consistent across lines
Previous pertuzumab (Yes): OS HR 0·70 (95% CI 0·46–1·06) vs No: 0·59 (0·38–0·93) — benefit regardless of pertuzumab history
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Regular approval May 2022 for HER2+ mBC after prior anti-HER2 regimen in metastatic setting (or recurrence within 6 months of neoadjuvant/adjuvant) [2] |
| EMA | Marketing authorization for 2L HER2+ mBC |
⚠️ Verify current regulatory status before prescribing.
NCCN: Preferred regimen for HER2+ mBC in second-line setting (Category 1) [3]
⚡ Grey Zones
- Optimal third-line therapy after T-DXd progression (T-DM1 vs tucatinib-based vs other) is unresolved by direct evidence
- 17% of T-DM1 patients received subsequent T-DXd — may attenuate the observed OS difference; no crossover-adjusted analysis reported
- Brain metastases subgroup OS HR (0·54) crossed 1·0 — intracranial benefit remains uncertain vs tucatinib
- HR-positive subgroup OS HR (0·76) crossed 1·0 — raises question of whether HR co-expression modifies T-DXd benefit
- Late-onset ILD risk beyond 2 years incompletely characterized with 29% of patients still on treatment
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5
- Enhertu (fam-trastuzumab deruxtecan-nxki) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
- Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.